Gyala Therapeutics

gyalatx.com ↗ ·Barcelona ·Series A

Gyala Therapeutics is a Barcelona-based, clinical-stage biotech spun off in 2020 from Hospital Clínic Barcelona and IDIBAPS, developing CAR-T cell therapies for hematologic cancers. Its lead candidate, GYA01, is a first-in-class CAR-T targeting the CD84 antigen, now in a Phase I/IIa trial for relapsed/refractory acute myeloid leukemia (AML) and T-cell acute lymphoblastic leukemia (T-ALL). The company has raised roughly €11M to date from private investors plus Spanish public innovation grants (NEOTEC, CDTI).

Founded

2020

Founders

Total funds raised

€5M

SectorsBiotechnology, Cell Therapy, Oncology, Immunotherapy Start-up MapHealthtech & Bio › Drug discovery & therapeutics developers

Suggest a correction

Founders

Claudio Santos

Co-Founder & Chief Executive Officer

Also at Invivo Partners →

Manel Juan

Co-Founder & Senior Scientific Advisor

Global models 5

Sana Biotechnology

United States · sana.com ↗

VC-backed clinical-stage cell therapy company engineering CAR-based and other cell therapies, one of the largest-ever private biotech venture raises before its 2021 IPO.

$700MComparable

Allogene Therapeutics

United States · www.allogene.com ↗

Clinical-stage biotech developing allogeneic CAR-T cell therapies for hematologic and solid cancers, raised via record-setting Series A/B rounds pre-IPO.

$373MComparable

Century Therapeutics

United States · www.centurytx.com ↗

Clinical-stage biotech engineering iPSC-derived CAR-T/CAR-NK cell therapies for cancer, matching Gyala's cell-therapy-for-hematologic-malignancy model.

$250MComparable

Poseida Therapeutics

United States · poseida.com ↗

Clinical-stage biotech developing next-generation CAR-T therapies for hematologic malignancies using non-viral gene engineering, closely paralleling Gyala's approach.

$228MComparable

Autolus Therapeutics

United Kingdom · www.autolus.com ↗

European clinical-stage biotech (academic spin-out, like Gyala) developing programmed CAR-T cell therapies for leukemias and lymphomas.

$150MComparable

In the same niche 67 others

See all in the Start-ups Map →

Highlight Therapeutics

+61 more →

Notes: Most funded first

Investors 3

Open as list →

Invivo Partners

invivo.partners

3 rounds, led 1 · 2020–25 Spain

Centro para el Desarrollo Tecnológico y la Innovación

www.cdti.es

2 rounds · 2024–25 Spain

Nara Capital

www.nara.capital/en

2 rounds · 2024–25 Spain

Funding rounds 3

·1 not counted

Date	Round	Amount	Lead
2025-09-15	Series A (estimated)	€3M	Lead not disclosed +3 more
2024-10-14	Series A	€540K partial: only one investor's ticket was disclosed	Lead not disclosed +3 more
2020-05-26	Seed	€1.5M	Invivo Ventures

Not counted (1)

Not counted in totals

2026-02-11

Grant

€3.7M

Lead unknown

+1 more

News 5

Open as list →

Published	Article
2026-02-10	Gyala Therapeutics initiates Phase I/IIa clinical trial of a CAR-T cell therapy in acute leukemias with limited treatment options ↗ PR Newswire 2026-02-10
2025-09-15	Gyala Therapeutics Raises €3M in Funding ↗ FinSMEs +1 source 2 reportsfirst 2025-09-15 Gyala Therapeutics Raises €3M in FundingFinSMEs · 2025-09-15↗ Gyala Therapeutics: €3 Million Secured To Advance CD84-Targeting CAR-T Therapy For Hard-To-Treat LeukemiasPulse 2.0 · 2025-09-19↗ 2025-09-15
2025-09-15	Gyala Therapeutics unveils first-in-class CAR-T therapy targeting CD84 showing strong preclinical efficacy in hard-to-treat leukemias ↗ PR Newswire 2025-09-15
2024-10-14	El CDTI Innovación invierte, junto con NARA Health Capital, en Gyala Therapeutics SL, biotech que desarrolla una nueva inmunoterapia basada en la tecnología CAR-T ↗ Capital-Riesgo.es 2024-10-14
2020-05-26	A new cancer immune therapy spin-off of Hospital Clínic-IDIBAPS secures a 1.5 million-euro investment from Invivo Ventures ↗ Hospital Clínic Barcelona 2020-05-26